The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

$468 $279 for your first year. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Offer available here until 24th October.

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

By Dani Blum The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes ...

Jelly Roll's wife Bunnie XO said she got sick and "s--t my brains out" after "microdosing" the weight loss drug tirzepatide, which is often marketed as Mounjaro or Zepbound.

Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources ...

I’ve gone through countless diets, workout plans ... which helps control eating and reduce calorie intake. Zepbound™ is an appetite suppressant that affects certain chemical signals in ...

Hypertension is a very common condition, affecting about half of all adults in the U.S. But it doesn’t always have symptoms, ...

Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...

Eli Lilly's $4.5 billion investment aims to expand its drug pipeline and build on the success of Mounjaro and Zepbound. Despite short-term stock volatility, long-term prospects remain bullish as ...